Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry
- PMID: 25242555
- DOI: 10.1016/j.eururo.2014.08.074
Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry
Abstract
Background: Few studies have reported on late declines and long-term health-related quality of life (HRQOL) after prostate cancer (PCa) treatment.
Objective: We assessed long-term HRQOL following various treatments for localized PCa.
Design, setting, and participants: This cohort study of HRQOL up to 10 yr after treatment used a prospectively accrued, nationwide PCa registry that collects longitudinal patient-reported HRQOL.
Intervention: Various primary treatments for localized PCa.
Outcome measurements and statistical analysis: The Medical Outcomes Studies 36-item Short Form and the University of California, Los Angeles, Prostate Cancer Index characterized physical function, mental health, and sexual, urinary, and bowel function and bother. Repeated measures mixed-model analysis assessed change in HRQOL by treatment over time, and logistic regression was used to measure the likelihood of a clinically significant decline in HRQOL.
Results and limitations: Among 3294 men, 1139 (34%) underwent nerve-sparing radical prostatectomy (NSRP), 860 (26%) underwent non-NSRP, 684 (21%) underwent brachytherapy, 386 (12%) underwent external beam radiotherapy, 161 (5%) underwent primary androgen deprivation therapy, and 64 (2%) pursued watchful waiting/active surveillance. Median follow-up was 74 mo (interquartile range: 50-102). Most treatments resulted in early declines in HRQOL, with some recovery over the next 1-2 yr and a plateau in scores thereafter. Surgery had the largest impact on sexual function and bother and on urinary function, radiation had the strongest effect on bowel function, and androgen deprivation therapy had the strongest effect on physical function. The main limitation was attrition among the cohort.
Conclusions: Although most men experience initial declines in HRQOL in the first 2 yr after treatment, there is little change from 3 to 10 yr and most differences between treatments attenuated over time.
Patient summary: Various treatments for prostate cancer result in a distinct constellation of adverse effects on health-related quality of life, which may have a long-term impact. These findings are helpful regarding shared decision making over choice of primary treatment.
Keywords: HRQOL; Prostate cancer; Treatment.
Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Comment in
-
Quality of life after primary treatment for localized prostate cancer: long-term considerations.Eur Urol. 2015 Oct;68(4):609-10. doi: 10.1016/j.eururo.2014.12.003. Epub 2014 Dec 18. Eur Urol. 2015. PMID: 25533419 No abstract available.
Similar articles
-
Impact of age on quality-of-life outcomes after treatment for localized prostate cancer.Eur Urol. 2015 Sep;68(3):480-6. doi: 10.1016/j.eururo.2015.01.008. Epub 2015 Feb 2. Eur Urol. 2015. PMID: 25656807
-
Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.JAMA. 2020 Jan 14;323(2):149-163. doi: 10.1001/jama.2019.20675. JAMA. 2020. PMID: 31935027 Free PMC article.
-
Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer.Eur Urol. 2024 Jun;85(6):565-573. doi: 10.1016/j.eururo.2023.09.024. Epub 2023 Oct 17. Eur Urol. 2024. PMID: 37858454
-
The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer.Urology. 2001 Aug;58(2 Suppl 1):94-100. doi: 10.1016/s0090-4295(01)01250-x. Urology. 2001. PMID: 11502459 Review.
-
Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.Prescrire Int. 2012 Oct;21(131):242-8. Prescrire Int. 2012. PMID: 23185849 Review.
Cited by
-
Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (18F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer.J Urol. 2017 Mar;197(3 Pt 1):676-683. doi: 10.1016/j.juro.2016.09.117. Epub 2016 Oct 13. J Urol. 2017. PMID: 27746282 Free PMC article.
-
Barriers and facilitators of shared decision-making in prostate cancer screening in primary care: A systematic review.Prev Med Rep. 2023 Dec 12;37:102539. doi: 10.1016/j.pmedr.2023.102539. eCollection 2024 Jan. Prev Med Rep. 2023. PMID: 38179441 Free PMC article. Review.
-
The Effect of Start and Stop Age at Screening on the Risk of Being Diagnosed with Prostate Cancer.J Urol. 2016 May;195(5):1390-1396. doi: 10.1016/j.juro.2015.11.062. Epub 2015 Dec 8. J Urol. 2016. PMID: 26678954 Free PMC article. Clinical Trial.
-
Utilization and predictors of expectant management among elderly men with low-and intermediate-risk localized prostate cancer in U.S. urological practice.Urol Pract. 2017 Mar;4(2):132-139. doi: 10.1016/j.urpr.2016.05.005. Urol Pract. 2017. PMID: 28808670 Free PMC article.
-
'I'm not a chance taker': A mixed methods exploration of factors affecting prostate cancer treatment decision-making.Ethn Health. 2021 Nov;26(8):1143-1162. doi: 10.1080/13557858.2019.1606165. Epub 2019 Apr 15. Ethn Health. 2021. PMID: 30987436 Free PMC article.